STING1 and cancer: Despite being the first STING agonist ever investigated in a clinical trial for cancer treatment, DMXAA failed to induce a clinical response due to its inability to bind human STING.[68] Ever since a couple of clinical trials with STING agonists in a monotherapy setting have been started (Table2).